Trial Profile
Phase II Trial of Bevacizumab Plus Etoposide for Patients With Recurrent Malignant Glioma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 May 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Etoposide (Primary)
- Indications Glioma
- Focus Therapeutic Use
- 01 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Aug 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 27 Feb 2008 New trial record.